摘要:
The present invention is related to a nucleic acid molecule capable of binding to SDF-1, preferably capable of inhibiting SDF-1, whereby the nucleic acid molecule is for use in a method for the treatment and/or prevention of a disease or disorder, for use in a method for the treatment of a subject suffering from a disease or disorder or being at risk of developing a disease or disorder as an adjunct therapy, or for use as a medicament for the treatment and/or prevention of a disease or disorder, whereby the disease or disorder is cancer.
摘要:
The present invention is related to a nucleic acid molecule, preferably binding to SDF-1, selected from the group comprising type A nucleic acid molecules, type B nucleic acid molecules, type C nucleic acid molecules and nucleic acid molecules having a nucleic acid sequence according to any of SEQ ID NO:142, SEQ ID NO:143 or SEQ ID NO:144.
摘要翻译:本发明涉及优选与SDF-1结合的核酸分子,所述核酸分子选自包含A型核酸分子,B型核酸分子,C型核酸分子和核酸分子的核酸分子,所述核酸分子具有根据 至SEQ ID NO:142,SEQ ID NO:143或SEQ ID NO:144中的任一个。
摘要:
The present invention is related to a nucleic acid, preferably binding to C5a, selected from the group comprising type A nucleic acids, type B nucleic acids, type C nucleic acids, type D nucleic acids and nucleic acids having a nucleic acid sequence according to any of SEQ.ID.No. 73 to 79.
摘要:
The present invention is related to a nucleic acid, preferably binding to MCP-1, selected from the group comprising type 1A nucleic acids, type 1B nucleic acids, type 2 nucleic acids, type 3 nucleic acids, type 4 nucleic acids and nucleic acids having a nucleic acid sequence according to any of SEQ. ID. No. 87 to 115.
摘要翻译:本发明涉及优选结合MCP-1的核酸,其选自1A型核酸,1B型核酸,2型核酸,3型核酸,4型核酸和具有 根据SEQ ID NO:6中任一项所述的核酸序列。 ID。 第87至115号。
摘要:
The present invention is related to a nucleic acid molecule capable of binding to MCP-I, whereby the nucleic acid molecule is for use as a medicament for the treatment and/or prevention of a chronic disease or chronic disorder, preferably selected from the group consisting of chronic respiratory disease, chronic kidney disease and systemic lupus erythematosus.
摘要:
The present invention is related to a nucleic acid, preferably binding to MCP-1, selected from the group comprising type 1A nucleic acids, type 1B nucleic acids, type 2 nucleic acids, type 3 nucleic acids, type 4 nucleic acids and nucleic acids having a nucleic acid sequence according to any of SEQ. ID. No. 87 to 115.
摘要翻译:本发明涉及优选结合MCP-1的核酸,其选自1A型核酸,1B型核酸,2型核酸,3型核酸,4型核酸和具有 根据SEQ ID NO:6中任一项所述的核酸序列。 ID。 第87至115号。
摘要:
The present invention is related to a nucleic acid, preferably binding to MCP-1, selected from the group consisting of Type 1A nucleic acids, type 1B nucleic acids, Type 2 nucleic acids, Type 3 nucleic acids, Type 4 nucleic acids and nucleic acids comprising SEQ ID NOs:87-115
摘要翻译:本发明涉及优选结合MCP-1的核酸,其选自1A型核酸,1B型核酸,2型核酸,3型核酸,4型核酸和核酸 包含SEQ ID NO:87-115
摘要:
The present invention is related to a nucleic acid, preferably binding to C5a, selected from the group comprising type A nucleic acids, type B nucleic acids, type C nucleic acids, type D nucleic acids and nucleic acids having a nucleic acid sequence according to any of SEQ.ID.No. 73 to 79.